| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$45.6M | ROE | −30.23% |
| Net Margin | — | ROIC | −33.90% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis and non-IPF interstitial lung disease, as well as refractory chronic cough. Its candidate Haduvio is an oral extended-release formulation of nalbuphine being studied in phase 2b and phase 2a trials. The company holds a license agreement with Keenova Therapeutics to develop nalbuphine hydrochloride products.
| Market Cap | $2.62B | Trading Days | 1811 |
| 52W High | 20.22 |
| 52W Low | 6.55 |
| % Off High | −8.85% |
| YTD | 47.20% | 1Y | 141.23% |
| 3Y | 704.80% | 5Y | 876.17% |
| Since incept. (ann.) | 12.46% |
| Ann. Volatility (1Y) | 63.95% | Ann. Volatility (3Y) | 74.94% |
| Sharpe (1Y) | 1.73 | Sharpe (3Y) | 1.29 |
| Max Drawdown (1Y) | −29.50% | Max Drawdown (3Y) | −56.88% |
| Beta (3Y, vs SPY) | −0.16 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| GRTX | Galera Therapeutics, Inc. | $2.61B | 25.4 |
| IMNM | Immunome Inc. | $2.63B | — |
| ATAI | AtaiBeckley Inc. | $2.64B | — |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.56B | — |
| NRIX | Nurix Therapeutics, Inc. | $2.51B | — |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | $2.77B | — |
| PBH | Prestige Consumer Healthcare Inc. | $2.45B | 13.2 |
| IRON | Disc Medicine, Inc. | $2.85B | — |
| MBX | MBX Biosciences, Inc. | $2.86B | — |
| VERA | Vera Therapeutics, Inc. | $2.39B | — |
| NKTR | NEKTAR THERAPEUTICS | $2.39B |
| CUE | Cue Biopharma, Inc. | $2.87B | — |
